Ultragenyx to Join Investor Conferences
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on developing and commercializing innovative therapies for serious rare and ultrarare genetic diseases, has announced its involvement in three important investor conferences.
Morgan Stanley Annual Global Healthcare Conference
On September 4, Emil Kakkis, M.D., Ph.D., the CEO and President of Ultragenyx, will take part in a fireside chat and hold one-on-one meetings at the Morgan Stanley 22nd Annual Global Healthcare Conference. This event provides an excellent opportunity for investors and stakeholders to gain valuable insights into the company's strategic direction and ongoing initiatives.
Cantor Global Healthcare Conference
Emil Kakkis will be joined by Howard Horn, Chief Financial Officer, at the Cantor Global Healthcare Conference on September 17. They will engage in a fireside chat and conduct one-on-one meetings, offering detailed information about the company's latest advancements and strategies.
Bank of America Global Healthcare Conference
On September 18, Eric Crombez, M.D., Chief Medical Officer, and Joshua Higa, Vice President of Investor Relations, will represent Ultragenyx at the Bank of America Global Healthcare Conference. They will discuss the company's commitment to addressing rare genetic diseases and participate in a fireside chat along with one-on-one meetings with investors and analysts.
Webcasting Events
Live and archived webcasts of these fireside chats will be accessible on the official Ultragenyx website, allowing a wider audience to engage with the discussions and insights shared during these conferences.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is dedicated to advancing the development of new therapies for patients suffering from serious rare and ultrarare genetic diseases. By concentrating on conditions with significant unmet medical needs, the company strives to offer improved healthcare solutions where previous options were limited or unavailable.
With a management team that possesses extensive experience in drug development and commercialization, Ultragenyx prioritizes efficient drug development processes. Their goal is to ensure the swift and effective delivery of innovative therapies to patients in need. The company focuses on providing therapeutic options that enhance quality of life and address the underlying causes of genetic disorders.
Contact Information
For any inquiries related to investor relations, please reach out to Joshua Higa at ir@ultragenyx.com.
Frequently Asked Questions
What is the purpose of Ultragenyx's participation in these conferences?
Ultragenyx participates in these conferences to share insights about their developments in rare genetic disease therapeutics and engage with investors.
Who is the CEO of Ultragenyx Pharmaceutical Inc.?
The CEO of Ultragenyx Pharmaceutical Inc. is Emil Kakkis, M.D., Ph.D.
When is the Morgan Stanley Annual Global Healthcare Conference?
The Morgan Stanley 22nd Annual Global Healthcare Conference is scheduled for September 4.
Which conferences will Ultragenyx attend in September?
Ultragenyx will attend the Morgan Stanley Annual Global Healthcare Conference, Cantor Global Healthcare Conference, and Bank of America Global Healthcare Conference in September.
Where can I view the webcasts of the conferences?
The webcasts of the conferences will be available on the Ultragenyx official website.